Tag: Eluvia

ELUVIA

Endovascular intervention for the treatment of femoropopliteal lesions: ELUVIA is safe...

This advertorial is sponsored by Boston Scientific. Boston Scientific leads the largest clinical programme investigating drug-eluting therapy for the treatment of peripheral arterial disease (PAD),...

CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies...

NOTE: ONLY intended for healthcare professionals outside of the USA and France. Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...

Only Eluvia Uses a Polymer for Controlled, Targeted Delivery of the...

Eluvia DES is the only technology that uses polymer-based drug delivery to treat Peripheral Artery Disease (PAD). Its polymer ensures that the majority of...

Positive outcomes for Eluvia stent in long lesion IMPERIAL sub-study

Clinical outcomes from the IMPERIAL Long Lesion Sub-study were presented at VIVA (5–8 November, Las Vegas, USA) demonstrating that the Eluvia drug-eluting vascular stent...

Eluvia outperforms Zilver PTX in IMPERIAL 12-month results

The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...

Eluvia paclitaxel-eluting stent shows long-term freedom from revascularisation at three years

Boston Scientific has announced the three-year results from the MAJESTIC trial for the Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological...